Skip to content
2000
image of Mendelian Randomization Combined with Experimental Validation Identifies Prognostic Genes LMNB1 and PLXNB2 in the Immune Response in Multiple Myeloma
file format pdf download PDF

Abstract

Introduction

Immune regulatory genes, such as PLXNB2, play critical roles in the tumor microenvironment, yet their specific functions in Multiple Myeloma (MM) remain largely unclear.

Methods

Transcriptomic and clinical data for MM were retrieved from the Gene Expression Omnibus (GEO) database and analyzed alongside immune regulation-related genes identified from previous Mendelian randomization analysis. Correlations between these genes and immune functions, clinical risk scores, and survival prognosis were evaluated. Virtual drug sensitivity screening was performed for MM immune-related prognostic risk genes. experiments, including cell cloning, Transwell assays, scratch tests, and ELISA, were conducted to validate findings.

Results

PLXNB2 expression was positively correlated with improved MM prognosis, whereas LMNB1 expression showed a negative correlation. MM cell lines exhibited reduced PLXNB2 and increased LMNB1 expression. Overexpression of PLXNB2 and knockdown of LMNB1 significantly inhibited MM cell proliferation, invasion, and migration. Furthermore, these manipulations decreased PD1 and CTLA-4 expression, enhancing the cytotoxic activity of immune cells against MM cells.

Discussion

Our findings highlight the potential immune regulatory functions of PLXNB2 and LMNB1 in MM progression. The interplay between these genes may influence immune evasion and tumor aggressiveness, providing insights into potential therapeutic targets.

Conclusion

Reduced PLXNB2 expression may drive LMNB1 upregulation, suppress immune cell responses, and promote MM progression. These genes represent promising biomarkers and therapeutic targets for improving MM treatment strategies.

© 2025 The Author(s). Published by Bentham Science Publishers.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/pra/10.2174/0115748928367765250925145654
2025-10-08
2026-03-01

  • From This Site

    /content/journals/pra/10.2174/0115748928367765250925145654
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/pra/10.2174/0115748928367765250925145654/BMS-PRA-2025-21.html?itemId=/content/journals/pra/10.2174/0115748928367765250925145654&mimeType=html&fmt=ahah

References

  1. Dimopoulos M.A. Moreau P. Terpos E. et al Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up. HemaSphere 2021 5 2 e528 33554050
    [Google Scholar]
  2. Padala S.A. Barsouk A. Barsouk A. et al Epidemiology, staging, and management of multiple myeloma. Med. Sci. 2021 9 1 3 10.3390/medsci9010003 33498356
    [Google Scholar]
  3. Liu J. Liu W. Mi L. et al Incidence and mortality of multiple myeloma in China, 2006–2016: An analysis of the Global Burden of Disease Study 2016. J. Hematol. Oncol. 2019 12 1 136 10.1186/s13045‑019‑0807‑5 31823802
    [Google Scholar]
  4. Silberstein J. Tuchman S. Grant S.J. What is multiple myeloma? JAMA 2022 327 5 497 10.1001/jama.2021.25306 35103765
    [Google Scholar]
  5. Grant S.J. Wildes T.M. Rosko A.E. Silberstein J. Giri S. A real‐world data analysis of predictors of early mortality after a diagnosis of multiple myeloma. Cancer 2023 129 13 2023 2034 10.1002/cncr.34760 36989073
    [Google Scholar]
  6. Garfall A.L. New biological therapies for multiple myeloma. Annu. Rev. Med. 2024 75 1 13 29 10.1146/annurev‑med‑050522‑033815 37729027
    [Google Scholar]
  7. McCachren S.S. Dhodapkar K.M. Dhodapkar M.V. Co-evolution of immune response in multiple myeloma: Implications for immune prevention. Front. Immunol. 2021 12 632564 10.3389/fimmu.2021.632564 33717170
    [Google Scholar]
  8. Ismael A. Robinette A.J. Huric L. et al CREB1 promotes expression of immune checkpoint HLA-E leading to immune escape in multiple myeloma. Leukemia 2024 38 8 1777 1786 10.1038/s41375‑024‑02303‑w 38902472
    [Google Scholar]
  9. Swamydas M. Murphy E.V. Ignatz-Hoover J.J. Malek E. Driscoll J.J. Deciphering mechanisms of immune escape to inform immunotherapeutic strategies in multiple myeloma. J. Hematol. Oncol. 2022 15 1 17 10.1186/s13045‑022‑01234‑2 35172851
    [Google Scholar]
  10. Caserta S. Innao V. Musolino C. Allegra A. Immune checkpoint inhibitors in multiple myeloma: A review of the literature. Pathol. Res. Pract. 2020 216 10 153114 10.1016/j.prp.2020.153114 32853951
    [Google Scholar]
  11. Nedal T.M.V. Moen S.H. Roseth I.A. et al Diet-induced obesity reduces bone marrow T and B cells and promotes tumor progression in a transplantable Vk*MYC model of multiple myeloma. Sci. Rep. 2024 14 1 3643 10.1038/s41598‑024‑54193‑8 38351079
    [Google Scholar]
  12. Kang C. Teclistamab: First approval. Drugs 2022 82 16 1613 1619 10.1007/s40265‑022‑01793‑1 36352205
    [Google Scholar]
  13. Guo Y. Quijano Cardé N.A. Kang L. et al Teclistamab: Mechanism of action, clinical, and translational science. Clin. Transl. Sci. 2024 17 1 e13717 10.1111/cts.13717 38266057
    [Google Scholar]
  14. Liu Y. Yan H. Gu H. et al Myeloma-derived IL-32γ induced PD-L1 expression in macrophages facilitates immune escape via the PFKFB3-JAK1 axis. OncoImmunology 2022 11 1 2057837 10.1080/2162402X.2022.2057837 35371618
    [Google Scholar]
  15. Schmidts A. Ormhøj M. Choi B.D. et al Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma. Blood Adv. 2019 3 21 3248 3260 10.1182/bloodadvances.2019000703 31698455
    [Google Scholar]
  16. Went M. Cornish A.J. Law P.J. et al Search for multiple myeloma risk factors using Mendelian randomization. Blood Adv. 2020 4 10 2172 2179 10.1182/bloodadvances.2020001502 32433745
    [Google Scholar]
  17. Zhu W. Charwudzi A. li Q, Zhai Z, Hu L, Pu L. Lipid levels and multiple myeloma risk: Insights from Meta-analysis and mendelian randomization. Lipids Health Dis. 2024 23 1 299 10.1186/s12944‑024‑02289‑5 39285309
    [Google Scholar]
  18. Wang Q. Shi Q. Lu J. Wang Z. Hou J. Causal relationships between inflammatory factors and multiple myeloma: A bidirectional Mendelian randomization study. Int. J. Cancer 2022 151 10 1750 1759 10.1002/ijc.34214 35841389
    [Google Scholar]
  19. Zhu Y. Liu J. Wang B. Identification of biomarkers in multiple myeloma: A comprehensive study combining microarray analysis and Mendelian randomization. J. Cell. Mol. Med. 2024 28 12 e18504 10.1111/jcmm.18504 38923838
    [Google Scholar]
  20. Newman A.M. Liu C.L. Green M.R. et al Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015 12 5 453 457 10.1038/nmeth.3337 25822800
    [Google Scholar]
  21. Cowan A.J. Green D.J. Kwok M. et al Diagnosis and management of multiple myeloma. JAMA 2022 327 5 464 477 10.1001/jama.2022.0003 35103762
    [Google Scholar]
  22. Landgren O. Iskander K. Modern multiple myeloma therapy: Deep, sustained treatment response and good clinical outcomes. J. Intern. Med. 2017 281 4 365 382 10.1111/joim.12590 28205262
    [Google Scholar]
  23. Haertle L. Barrio S. Munawar U. et al Single-nucleotide variants and epimutations induce proteasome inhibitor resistance in multiple myeloma. Clin. Cancer Res. 2023 29 1 279 288 10.1158/1078‑0432.CCR‑22‑1161 36282272
    [Google Scholar]
  24. Lancman G. Moshier E. Cho H.J. et al Trial designs and endpoints for immune therapies in multiple myeloma. Am. J. Hematol. 2023 98 S2 S35 S45 10.1002/ajh.26753 36200130
    [Google Scholar]
  25. Stong N. Hagner P.R. Pierceall W.E. Methods for treating multiple myeloma. US Patent 20240132623 2024
    [Google Scholar]
  26. Chari A. Vogl D.T. Gavriatopoulou M. et al Oral selinexor–dexamethasone for triple-class refractory multiple myeloma. N. Engl. J. Med. 2019 381 8 727 738 10.1056/NEJMoa1903455 31433920
    [Google Scholar]
  27. Sonneveld P. Zweegman S. Cavo M. et al Carfilzomib, pomalidomide, and dexamethasone as second-line therapy for lenalidomide-refractory multiple myeloma. HemaSphere 2022 6 10 e786 10.1097/HS9.0000000000000786 36204691
    [Google Scholar]
  28. Voorhees P.M. Kaufman J.L. Laubach J. et al Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood 2020 136 8 936 945 10.1182/blood.2020005288 32325490
    [Google Scholar]
  29. Brundu S. Napolitano V. Franzolin G. et al Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. EMBO Mol. Med. 2023 15 3 e16104 10.15252/emmm.202216104 36722641
    [Google Scholar]
  30. Qin H. Lu Y. Du L. et al Pan-cancer analysis identifies LMNB1 as a target to redress Th1/Th2 imbalance and enhance PARP inhibitor response in human cancers. Cancer Cell Int. 2022 22 1 101 10.1186/s12935‑022‑02467‑4 35241075
    [Google Scholar]
  31. Xiang G. Cheng Y. MiR-126-3p inhibits ovarian cancer proliferation and invasion via targeting PLXNB2. Reprod. Biol. 2018 18 3 218 224 10.1016/j.repbio.2018.07.005 30054097
    [Google Scholar]
  32. Jelinek T. Hajek R. PD-1/PD-L1 inhibitors in multiple myeloma: The present and the future. OncoImmunology 2016 5 12 e1254856 10.1080/2162402X.2016.1254856 28123899
    [Google Scholar]
  33. IO BIOTECH APS. PDL1 peptides for use in cancer vaccines. US patent 20220372108 2022
    [Google Scholar]
  34. Costa L.J. Chhabra S. Medvedova E. et al Daratumumab, carfilzomib, lenalidomide, and dexamethasone with minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma. J. Clin. Oncol. 2022 40 25 2901 2912 10.1200/JCO.21.01935 34898239
    [Google Scholar]
  35. Janssen Biotech, Inc. Daratumumab and Hyaluronidase for the Treatment of Multiple Myeloma. US Patent 20210393775 2021
    [Google Scholar]
/content/journals/pra/10.2174/0115748928367765250925145654
Loading
Mendelian Randomization Combined with Experimental Validation Identifies Prognostic Genes LMNB1 and PLXNB2 in the Immune Response in Multiple Myeloma
Bentham Science Publishers ; https://doi.org/10.2174/0115748928367765250925145654
/content/journals/pra/10.2174/0115748928367765250925145654
/content/journals/pra/10.2174/0115748928367765250925145654
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher’s website along with the published article.

file format download Download

  • Article Type:     Research Article
Keywords: PLXNB2 ; Multiple myeloma ; immunotherapy ; immune response ; LMNB1 ; mendelian randomization analysis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test